Immunotherapy. 2013;5(9):923-925. Rather than focusing on the blockade of IL-17A or IL-17F alone, Wedebye Schmidt et al. examined the effects of blockade of both IL-17A and IL-17F. They report that ...
“Clinical trials and post-marketing surveillance of bimekizumab saw higher candidiasis,” said Disha Chakraborty, who presented the results at the Group for Research and Assessment of Psoriasis and ...
Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with the program entering the company’s clinical development portfolio.
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results